Abstract:Tumor angiogenesis is an essential process for supplying rapidly growing malignant tissues with essential nutrients and oxygen. An angiogenic switch allows tumor cells to survive and grow, and provides them access to vasculature resulting in metastatic disease. Monocyte-derived macrophages recruited and reprogrammed by tumor cells serve as a major source of angiogenic factors boosting the angiogenic switch. Tumor endothelium releases angiopoietin-2 and further facilitates recruitment of TIE2 receptor expressing monocytes (TEM) into tumor sites. Tumor-associated macrophages (TAM) sense hypoxia in avascular areas of tumors, and react by production of angiogenic factors such as VEGFA. VEGFA stimulates chemotaxis of endothelial cells (EC) and macrophages. In some tumors, TAM appeared to be a major source of MMP9. Elevated expression of MMP9 by TAM mediates extracellular matrix (ECM) degradation and the release of bioactive VEGFA. Other angiogenic factors released by TAM include basic fibroblast growth factor (bFGF), thymidine phosphorylase (TP), urokinase-type plasminogen activator (uPA), and adrenomedullin (ADM). The same factors used by macrophages for the induction of angiogenesis [like vascular endothelial growth factor A (VEGF-A) and MMP9] support lymphangiogenesis. TAM can express LYVE-1, one of the established markers of lymphatic endothelium. TAM support tumor lymphangiogenesis not only by secretion of pro-lymphangiogenic factors but also by trans-differentiation into lymphatic EC. New pro-angiogenic factor YKL-40 belongs to a family of mammalian chitinase-like proteins (CLP) that act as cytokines or growth factors. Human CLP family comprises YKL-40, YKL-39, and SI-CLP. Production of all three CLP in macrophages is antagonistically regulated by cytokines. It was recently established that YKL-40 induces angiogenesis in vitro and in animal tumor models. YKL-40-neutralizing monoclonal antibody blocks tumor angiogenesis and progression. The role of YKL-39 and SI-CLP in tumor angiogenesis and lymphangiogenesis remains to be investigated.

Different subpopulations of macrophages, neutrophils, mast cells, and fibroblasts are involved in the control of tumor angiogenesis

Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment

Targeting the Tumor Microenvironment: A Close Up of Tumor-Associated Macrophages and Neutrophils

Role of Bone Marrow-Derived Cells in Angiogenesis: Focus on Macrophages and Pericytes

Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy

Tumor-associated macrophages, dendritic cells, and neutrophils: biological roles, crosstalk, and therapeutic relevance

The impact of the immune system on tumor: angiogenesis and vascular remodeling

Immune cell networking in solid tumors: focus on macrophages and neutrophils

[Neutrophils in the tumor microenvironment-foes or friends?]

Targeting myeloid cells in the tumor sustaining microenvironment

Fibroblasts in the Tumor Microenvironment: Shield or Spear?

Microenvironmental regulation in tumor progression: Interactions between cancer-associated fibroblasts and immune cells

Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment

Microenvironmental regulation of tumour angiogenesis

Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis

Tumor-associated myeloid cells: diversity and therapeutic targeting

Tumor-Associated Myeloid Cells in Cancer Progression

Role of macrophages in tumor progression and therapy (Review)

Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism

The role of macrophages in the tumor microenvironment and tumor metabolism

Macrophage barrier in the tumor microenvironment and potential clinical applications